The company said that it will begin sales and marketing activities in the US, Europe and Australia. Pearl Fractional, with its proprietary 2,790nm wavelength, is the company’s solution for the fractional ablative market, said Cutera.
Kevin Connors, president and CEO of Cutera, said: Pearl Fractional targets the deep dermis to treat the signs of aging. Our team recognized the limitations of CO2 fractional lasers and designed our product to deliver a better experience to patients and physicians. Pearl Fractional produces a confined thermal zone in the dermis with the goal of reducing post-operative downtime, which we believe will result in greater patient interest.